United Therapeutics's 15min chart shows Bollinger Bands Narrowing and KDJ Death Cross.
ByAinvest
Thursday, Jun 26, 2025 9:47 am ET1min read
MESA--
The stock's recent performance has been marked by a narrowing of Bollinger Bands and a KDJ Death Cross at 06/26/2025 09:45. These technical indicators suggest a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, potentially signaling further decreases in the stock price.
As of the date of the recent transaction, shares of United Therapeutics Corp were trading at $289.99, giving the stock a market cap of $12.899 billion. The company's price-earnings ratio of 11.41 is lower than the industry median of 23.335, indicating that the stock may be undervalued. Additionally, the stock has a price-to-GF-Value ratio of 0.79, further suggesting that the stock is modestly undervalued based on its GuruFocus Value [1].
These developments warrant close attention from investors, as they may indicate a shift in the stock's momentum and potential future price movements. However, it is essential to consider these signals alongside other fundamental and technical indicators for a comprehensive analysis.
References:
[1] https://www.gurufocus.com/news/2946627/insider-sell-nilda-mesa-sells-shares-of-united-therapeutics-corp
UTHR--
United Therapeutics' 15-minute chart has triggered a narrowing of Bollinger Bands, in conjunction with a KDJ Death Cross at 06/26/2025 09:45. This suggests that the magnitude of stock price fluctuations is decreasing, and the momentum of the stock price is shifting towards the downside, potentially leading to further decreases.
United Therapeutics Corp (UTHR) has seen significant insider activity and technical indicators that may suggest a potential downturn in stock price. On June 24, 2025, Nilda Mesa, a Director at United Therapeutics, sold 645 shares, reducing her total holdings to 4,883 shares [1]. This sale is part of a broader trend, as Mesa has sold 1,390 shares over the past year without any purchases, while there have been 87 insider sells and 0 buys over the same period.The stock's recent performance has been marked by a narrowing of Bollinger Bands and a KDJ Death Cross at 06/26/2025 09:45. These technical indicators suggest a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, potentially signaling further decreases in the stock price.
As of the date of the recent transaction, shares of United Therapeutics Corp were trading at $289.99, giving the stock a market cap of $12.899 billion. The company's price-earnings ratio of 11.41 is lower than the industry median of 23.335, indicating that the stock may be undervalued. Additionally, the stock has a price-to-GF-Value ratio of 0.79, further suggesting that the stock is modestly undervalued based on its GuruFocus Value [1].
These developments warrant close attention from investors, as they may indicate a shift in the stock's momentum and potential future price movements. However, it is essential to consider these signals alongside other fundamental and technical indicators for a comprehensive analysis.
References:
[1] https://www.gurufocus.com/news/2946627/insider-sell-nilda-mesa-sells-shares-of-united-therapeutics-corp
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet